Paul M Ridker1, James Revkin1, Pierre Amarenco1, Robert Brunell1, Madelyn Curto1, Fernando Civeira1, Marcus Flather1, Robert J Glynn1, Jean Gregoire1, J Wouter Jukema1, Yuri Karpov1, John J P Kastelein1, Wolfgang Koenig1, Alberto Lorenzatti1, Pravin Manga1, Urszula Masiukiewicz1, Michael Miller1, Arend Mosterd1, Jan Murin1, Jose C Nicolau1, Steven Nissen1, Piotr Ponikowski1, Raul D Santos1, Pamela F Schwartz1, Handrean Soran1, Harvey White1, R Scott Wright1, Michal Vrablik1, Carla Yunis1, Charles L Shear1, Jean-Claude Tardif1. 1. From Brigham and Women's Hospital and Harvard Medical School, Boston (P.M.R., R.J.G.); Pfizer, New York (J.R., R.B., M.C., U.M., P.F.S., C.Y., C.L.S.); Paris-Diderot, Sorbonne Paris Cité University, Paris (P.A.); Universidad de Zaragoza, IIS Aragon, Zaragoza, Spain (F.C.); University of East Anglia, Norwich (M.F.), and Central Manchester University Hospital, Manchester (H.S.) - both in the United Kingdom; the Montreal Heart Institute, Université de Montréal, Montreal (J.G., J.-C.T.); Leiden University Medical Center, Leiden (J.W.J.), Academic Medical Center of the University of Amsterdam, Amsterdam (J.J.P.K.), and Meander Medical Center, Amersfoort (A.M.) - all in the Netherlands; Russian Cardiology Research and Production Center, Moscow (Y.K.); Deutsches Herzzentrum München, Technische Universität München, Munich Heart Alliance, Munich, Germany (W.K.); Cordoba Hospital, Cordoba, Argentina (A.L.); University of the Witwatersrand, Johannesburg (P.M.); University of Maryland, Baltimore (M.M.); University of Comenius, Bratislava, Slovakia (J.M.); Heart Institute, University of São Paulo Medical School (J.C.N.), and Lipid Clinic Heart Institute, University of São Paulo Medical School Hospital (R.D.S.), São Paulo; Cleveland Clinic Foundation, Cleveland (S.N.); Wroclaw Medical University, Wroclaw, Poland (P.P.); Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand (H.W.); Mayo Clinic, Rochester, MN (R.S.W.); and First Faculty of Medicine, Charles University, Prague, Czech Republic (M.V.).
Abstract
BACKGROUND:Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months. RESULTS: At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from baseline of 64.2% (P<0.001). In the lower-risk, shorter-duration trial (in which the patients had a baseline LDL cholesterol level of ≥70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P=0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of ≥100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P=0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P=0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001). CONCLUSIONS: In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients. (Funded by Pfizer; SPIRE-1 and SPIRE-2 ClinicalTrials.gov numbers, NCT01975376 and NCT01975389 .).
RCT Entities:
BACKGROUND:Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months. RESULTS: At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from baseline of 64.2% (P<0.001). In the lower-risk, shorter-duration trial (in which the patients had a baseline LDL cholesterol level of ≥70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P=0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of ≥100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P=0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P=0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001). CONCLUSIONS: In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients. (Funded by Pfizer; SPIRE-1 and SPIRE-2 ClinicalTrials.gov numbers, NCT01975376 and NCT01975389 .).
Authors: Zhengdong D Zhang; Sofiya Milman; Jhih-Rong Lin; Shayne Wierbowski; Haiyuan Yu; Nir Barzilai; Vera Gorbunova; Warren C Ladiges; Laura J Niedernhofer; Yousin Suh; Paul D Robbins; Jan Vijg Journal: Nat Metab Date: 2020-07-27
Authors: Ray Hu; Michael P Morley; Jeffrey Brandimarto; Nathan R Tucker; Victoria A Parsons; Sihai D Zhao; Benjamin Meder; Hugo A Katus; Frank Rühle; Monika Stoll; Eric Villard; François Cambien; Honghuang Lin; Nicholas L Smith; Janine F Felix; Ramachandran S Vasan; Pim van der Harst; Christopher Newton-Cheh; Jin Li; Cecilia E Kim; Hakon Hakonarson; Sridhar Hannenhalli; Euan A Ashley; Christine S Moravec; W H Wilson Tang; Marjorie Maillet; Jeffery D Molkentin; Patrick T Ellinor; Kenneth B Margulies; Thomas P Cappola Journal: Circ Genom Precis Med Date: 2018-03
Authors: Tina M Kaufman; Bruce A Warden; Jessica Minnier; Joshua R Miles; P Barton Duell; Jonathan Q Purnell; Cezary Wojcik; Sergio Fazio; Michael D Shapiro Journal: Circ Res Date: 2019-01-04 Impact factor: 17.367